Age- and region-specific hepatitis B prevalence in Turkey estimated using generalized linear mixed models: a systematic review

Toy M, Önder FO, Wörmann T, et al. Age- and region-specific hepatitis B prevalence in Turkey estimated using generalized linear mixed models: a systematic review. BMC infectious diseases. 2011;11(1): 337.BACKGROUND: To provide a clear picture of the current hepatitis B situation, the authors performed a systematic review to estimate the age- and region-specific prevalence of chronic hepatitis B (CHB) in Turkey. METHODS: A total of 339 studies with original data on the prevalence of hepatitis B surface antigen (HBsAg) in Turkey and published between 1999 and 2009 were identified through a search of electronic databases, by reviewing citations, and by writing to authors. After a critical assessment, the authors included 129 studies, divided into categories: 'age-specific'; 'region-specific'; and 'specific population group'. To account for the differences among the studies, a generalized linear mixed model was used to estimate the overall prevalence across all age groups and regions. For specific population groups, the authors calculated the weighted mean prevalence. RESULTS: The estimated overall population prevalence was 4.57, 95% confidence interval (CI): 3.58, 5.76, and the estimated total number of CHB cases was about 3.3 million. The outcomes of the age-specific groups varied from 2.84, (95% CI: 2.60, 3.10) for the 0-14-year olds to 6.36 (95% CI: 5.83, 6.90) in the 25-34-year-old group. CONCLUSION: There are large age-group and regional differences in CHB prevalence in Turkey, where CHB remains a serious health problem

Evaluation of the agreement of results obtained from ABI PRISM 7000 and 7700 sequencers in the quantification of hepatitis B virus DNA [Hepatit B virus DNA kantitasyonunda ABI Prism 7000 ile 7700 sekans saptama cihazlarinin sonuçlarinin birbiri ile uygunlugunun araştirilmasi]

PubMed ID: 16128028There are different methods and systems for quantification of HBV-DNA in clinical virology laboratories. The aim of this study was to evaluate the agreement of the polymerase chain reaction (PCR) protocol with ABI Prism 7000 instrument (PE Biosystems) which was designed and optimised for ABI Prism 7700 (PE Biosystems). Serum samples obtained from 168 chronic hepatitis B patients were treated with "High Pure Viral Nucleic Acid Kit" (Roche Applied Science, USA), and MagnaPure LC isolation station (Roche Applied Science, Germany) was used for HBV-DNA isolation. Real time PCR procedure which amplifies pre-S gene of HBV genome was performed. Amplification and detection steps of all samples were performed with ABI Prism 7700 and 7000 Sequence Detection Systems. Among 168 samples, results of 124 serum samples were found to be in dynamic ranges of the tests. The results of these 124 samples obtained from ABI 7000 and ABI 7700 were concordant. Among the rest of 44 samples; one yielded higher than 1010 copies/mL with two of the systems; six samples gave results higher than 1010 copies/mL only with 7700; thirty samples were found negative with both of the systems; seven samples were positive (320-1220 copies/mL) with 7000 but negative with 7700. As a result this PCR protocol can be used in ABI 7000 system according to viral quality control (VQC) results. However, since the results of samples with HBV-DNA less than 1×106 copy/ml were discordant with the results obtained by ABI 7700 system, it can be concluded that different systems must not be used for the management and monitoring of the same patient

Bacterial contamination in blood and blood products [Kan ve kan ürünlerinde bakteriyel kontaminasyon]

PubMed ID: 15900840Skin disinfection during phlebotomy is a critical step for bacterial contamination of blood and blood products. The aim of this study was to investigate the bacterial contamination rates during phlebotomy and to defect the probable microorganisms present. Skin disinfections of 100 blood donors were performed by using povidone iodine solution with standard procedure. Fifteen mililiters of blood samples were drawn from the transfusion set and inoculated into culture flasks of automated Bact/ Alert (BioMerieux) system. Blood cultures were monitorized for one week, and bacteria in positive cultures were identified by using classical microbiological methods in addition with API identification system (BioMerieux; ID32 Staph, 20 Strep). As a result, bacterial growth was detected in four (4%) of the blood samples, whereas 96% of the samples were found sterile. Staphylococcus epidermidis was the microorganism which had been grown in three of the samples, and Streptococcus mutans in one. The positivity rate detected in our study was considered high, since expected bacterial contamination rates in blood transfusions were between 0.2-0.5%. This data indicated that the procedures used in phlebotomy such as the choice of phlebotomy region, disinfectant use and disinfection time should be re-evaluated in our blood centre

Investigation of Hepatitis C virus genotype distribution in patients with chronic Hepatitis C infections in Antalya Training and Research Hospital, Turkey [Antalya Egitim ve Araştirma Hastanesinde Kronik Hepatit c hastalarinin genotip dagiliminin araştirilmasi]

PubMed ID: 25052115Hepatitis C virus (HCV) infection is a major global health problem due to high chronicity rates, occurrence of severe hepatic diseases, and absence of an accurate therapy and effective vaccine. It is well known that viral genome is highly variable and HCV has at least six genotypes, each of them containing a series of subtypes. HCV genotypes exhibit geographical and epidemiological distribution. Genotype identification is clinically important to decide the dosage and duration of treatment since different genotypes exhibit variable response to treatment. The aim of this study was to determine the HCV genotypes in chronic HCV patients who were followed-up in Antalya Research and Training Hospital, Turkey. Anti-HCV and HCV-RNA positive blood samples obtained from 148 chronic hepatitis C patients (67 female, 81 male; mean age: 50.5 ± 10.8, age range: 17-73 years) who were admitted to Antalya Research and Training Hospital Microbiology Laboratory during January 2011 -June 2013, were included in the study. Epidemiological data of the patients and HCV genotype results were evaluated retrospectively. Viral genotypes were determined by real-time (Rt) PCR assay (Abbott Molecular Diagnostic, USA). HCV genotype (Gt)-1 was detected in 119 (80.4%) of the patients, of them 15.9% (19/119) were identified as subtype 1 a and 75.6% (90/119) were subtype 1 b. The prevalence rates of Gt-2, -3, and -4 were found as 3.4% (n= 5), 11.5% (n= 17), and 2% (n= 3), respectively. Gt-6 was not detected in our patients. Mixed infection with HCV types was detected in four patients (2.7%) by Rt-PCR; of these three were detected as Gt-1 and one was Gt-2 by RFLP (Restriction Fragment Length Polymorphism) and sequencing. The high prevalence of Gt-3 (11.5%) obtained in this study was attributed to the determination of Gt-3 in seven of 13 foreign national subjects. Rt-PCR method used in this study is user independent, standardized, automated, rapid and reliable method, however in case of detection of mixed types, the samples should be confirmed by other methods. In conclusion, we reported that the majority of the chronic hepatitis C infected patients had Gt-1 b, and Gt-3 exhibited the highest rate ever reported by other studies from Turkey.Hepatitis C virus (HCV) infection is a major global health problem due to high chronicity rates, occurrence of severe hepatic diseases, and absence of an accurate therapy and effective vaccine. It is well known that viral genome is highly variable and HCV has at least six genotypes, each of them containing a series of subtypes. HCV genotypes exhibit geographical and epidemiological distribution. Genotype identification is clinically important to decide the dosage and duration of treatment since different genotypes exhibit variable response to treatment. The aim of this study was to determine the HCV genotypes in chronic HCV patients who were followed-up in Antalya Research and Training Hospital, Turkey. Anti-HCV and HCV-RNA positive blood samples obtained from 148 chronic hepatitis C patients (67 female, 81 male; mean age: 50.5 ± 10.8, age range: 17-73 years) who were admitted to Antalya Research and Training Hospital Microbiology Laboratory during January 2011 -June 2013, were included in the study. Epidemiological data of the patients and HCV genotype results were evaluated retrospectively. Viral genotypes were determined by real-time (Rt) PCR assay (Abbott Molecular Diagnostic, USA). HCV genotype (Gt)-1 was detected in 119 (80.4%) of the patients, of them 15.9% (19/119) were identified as subtype 1 a and 75.6% (90/119) were subtype 1 b. The prevalence rates of Gt-2, -3, and -4 were found as 3.4% (n= 5), 11.5% (n= 17), and 2% (n= 3), respectively. Gt-6 was not detected in our patients. Mixed infection with HCV types was detected in four patients (2.7%) by Rt-PCR; of these three were detected as Gt-1 and one was Gt-2 by RFLP (Restriction Fragment Length Polymorphism) and sequencing. The high prevalence of Gt-3 (11.5%) obtained in this study was attributed to the determination of Gt-3 in seven of 13 foreign national subjects. Rt-PCR method used in this study is user independent, standardized, automated, rapid and reliable method, however in case of detection of mixed types, the samples should be confirmed by other methods. In conclusion, we reported that the majority of the chronic hepatitis C infected patients had Gt-1 b, and Gt-3 exhibited the highest rate ever reported by other studies from Turkey

Anti-HTLV-I/II Seroprevalence in healthy blood donors in Izmir, Turkey

Human T-cell lymphotropic virus type I (HTLV-I) is the first human retrovirus to be associated with malignant disease-namely, adult T-cell leukemia/lymphoma. HTLV-I has also been associated with several diseases. HTLV-I has a worldwide distribution with major endemic foci in the Caribbean and Southern Japan. HTLV-II is a closely related retrovirus that shares considerable genomic homology with HTLV-I but has not been proven to be a pathogen. Major routes of transmission are blood transfusion, breast milk and sexual activity. In this study, we examined the seroprevalance of HTLV-I/II among healthy blood donors attended to Ege University Hospital in Izmir. 913 healthy blood donors were examined for the presence of anti-HTLV-l/ll antibody in their sera. Serum specimens were tested with an enzyme immunoassay (EIA) (Organon Teknika, Vironostika HTLV-I/II Microelisa System, Holland). All of the 913 healthy blood donors were seronegative with EIA. These findings indicate that screening of blood donors for HTLV I/II is not necessary at present time